D-0096-2023 Class III Terminated

Recalled by Jubilant Cadista Pharmaceuticals, Inc. — Salisbury, MD

FDA drug recall D-0096-2023 was initiated by Jubilant Cadista Pharmaceuticals, Inc. on Dec 27, 2022 and is designated Class III. Reason for recall: Subpotent Drug: Out of specification for assay at the 18-month stability timepoint. The recall status is terminated (terminated Dec 5, 2023). Affected quantity: 14,061 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 11, 2023
Initiation Date
Dec 27, 2022
Termination Date
Dec 5, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
14,061 bottles

Product description

Prochlorperazine Maleate Tablets, USP 5mg, 100 tablets, RX Only, Jubilant Cadista Pharmaceuticals, Inc., Salisbury, Maryland 21801, NDC 59746-113-06

Reason for recall

Subpotent Drug: Out of specification for assay at the 18-month stability timepoint.

Distribution pattern

Nationwide in the USA.

Code information

Lot#: 21P0336, Exp: 04/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0096-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0096-2023. Report a data issue: hello@regdatalab.com.